| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Institute for Translational Medicine and Therapeutics and Department of Pharmacology, and
Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
Decay-accelerating factor (DAF, CD55) is a GPI-anchored membrane protein that regulates complement activation on autologous cells. In addition to protecting host tissues from complement attack, DAF has been shown to inhibit CD4+ T cell immunity in the setting of model Ag immunization. However, whether DAF regulates natural T cell immune response during pathogenic infection is not known. We describe in this study a striking regulatory effect of DAF on the CD8+ T cell response to lymphocytic choriomeningitis virus (LCMV) infection. Compared with wild-type mice, DAF knockout (Daf-1–/–) mice had markedly increased expansion in the spleen of total and viral Ag-specific CD8+ T cells after acute or chronic LCMV infection. Splenocytes from LCMV-infected Daf-1–/– mice also displayed significantly higher killing activity than cells from wild-type mice toward viral Ag-loaded target cells, and Daf-1–/– mice cleared LCMV more efficiently. Importantly, deletion of the complement protein C3 or the receptor for the anaphylatoxin C5a (C5aR) from Daf-1–/– mice reversed the enhanced CD8+ T cell immunity phenotype. These results demonstrate that DAF is an important regulator of CD8+ T cell immunity in viral infection and that it fulfills this role by acting as a complement inhibitor to prevent virus-triggered complement activation and C5aR signaling. This mode of action of DAF contrasts with that of CD59 in viral infection and suggests that GPI-anchored membrane complement inhibitors can regulate T cell immunity to viral infection via either a complement-dependent or -independent mechanism.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by Grants AI-49344, AI-44970, and AI-62388 from the National Institutes of Health.
2 Address correspondence and reprint requests to Dr. Wen-Chao Song, Institute for Translational Medicine and Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, 1254 Biomedical Research Building II/III, 421 Curie Boulevard, Philadelphia, PA 19104. E-mail address: Song{at}spirit.gcrc.upenn.edu
3 Abbreviations used in this paper: DAF, decay-accelerating factor; LCMV, lymphocytic choriomeningitis virus; CD62L, CD62 ligand; MOG, myelin oligodendrocyte glycoprotein; WT, wild type.
This article has been cited by other articles:
|
|
 |
|
  V. Pavlov, H. Raedler, S. Yuan, S. Leisman, W.-h. Kwan, P. N. Lalli, M. E. Medof, and P. S. Heeger Donor Deficiency of Decay-Accelerating Factor Accelerates Murine T Cell-Mediated Cardiac Allograft Rejection J. Immunol., October 1, 2008; 181(7): 4580 - 4589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Lalli, M. G. Strainic, M. Yang, F. Lin, M. E. Medof, and P. S. Heeger Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis Blood, September 1, 2008; 112(5): 1759 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Varela, M. Imai, C. Atkinson, R. Ohta, M. Rapisardo, and S. Tomlinson Modulation of Protective T Cell Immunity by Complement Inhibitor Expression on Tumor Cells Cancer Res., August 15, 2008; 68(16): 6734 - 6742. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
